Etrinabdione

Etrinabdione (EHP-101; VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. Etrinabdione inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. Etrinabdione, a semi-synthetic multitarget cannabinoquinoid, has potent anti-inflammatory activity. Etrinabdione attenuates adipogenesis and prevents diet-induced obesity[1][2].

Product Specifications

CAS Number

[1818428-24-8]

Product Name Alternative

EHP-101; VCE-004.8

UNSPSC

12352005

Target

Cannabinoid Receptor; HIF/HIF Prolyl-Hydroxylase; PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-anti-virus

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/etrinabdione.html

Purity

99.16

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1C(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(C(NCC3=CC=CC=C3)=C1CCCCC)=O

Molecular Formula

C28H35NO3

Molecular Weight

433.58

References & Citations

[1]Navarrete C, et al. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. J Neuroinflammation. 2018 Mar 1;15 (1) :64.|[2]Palomares B, et al. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. Sci Rep. 2018 Oct 31;8 (1) :16092.